404 Page not found

Sort by

It appears the page you were searching for can't be found. Try using the search box below to find what you were looking for.

58 Results

Search results

    Genomic Health Q4 Revenues Up 6 Percent; Plans to Reduce Staff by 10 Percent

    Article: Breaking News—in Business News

    The company fell short of Wall Street expectations on the top and bottom lines and said it plans on making some significant changes for 2018, including shutting down its liquid biopsy testing. 

    Labs Mull New Regulatory Path for NGS Tumor Panels in Wake of FDA Decision on MSK-IMPACT

    Article: In-Depth—in Molecular Diagnostics

    The authorization implements regulatory strategies the FDA advanced with industry stakeholders, though labs may still be more inclined to take the CLIA route, as long as it is available.

    The team has received around $900,000 in National Cancer Institute funding to develop new capabilities for CIVIC, improve curation, and engage with the community.

    Two of the firm's assays were evaluated in posters presented at a recent conference, demonstrating good performance relative to commonly used non-molecular methods.

    Abbott Molecular has been building a PCR-based system from the ground up and plans to sell it in parallel with the m2000, eventually replacing that system.

    The year in personalized medicine started at the White House and ended with a congressional hearing, capturing the enthusiasm and barriers in the field.

    The method simplifies previous techniques, and preliminary testing using a microfluidic device indicates it could ultimately be used in low-resource settings.

    Will the President's Plan Move Precision Medicine Beyond the Hype?

    Article: Breaking News—in Policy & Legislation

    The initiative is exciting for personalized medicine advocates, but they find that many key details need to be worked out for this large scale effort to be successful.

    Luminex Q4 Revenues Grow 5 Percent on Assay Sales

    Article: Breaking News—in Business News

    Luminex reported $58.1 million in revenues compared to $55.2 million in the year-ago period and essentially on par with analysts' consensus estimate of $58.3 million.

    Biocept Launches Blood-based Lung Cancer Dx to Guide Therapy in Patients Lacking Tissue Biopsy

    Article: In-Depth—in Companion Diagnostics

    The company launched a blood-based diagnostic to guide treatment strategies for lung cancer patients with ALK fusions who don't have sufficient tumor biopsy material for analysis by tissue-based tests.

    A cadre of AMP members descended on Capitol Hill to educate legislators on what they believe would be a negative impact of FDA regulation on the MDx industry.

    Originally published Nov. 11.

    Originally published Aug. 5.

    As advanced diagnostic technologies probe deeper into the human genome, revealing previously uncharacterized markers in patients and families, so-called variants of unknown significance (VUS) are becoming an unavoidable challenge for clinical labs using genomic data to diagnose p

    NEW YORK (GenomeWeb News) – For the past eight years Menon Biosensors has operated in near secrecy developing a technology with US government backing to detect some of the world's deadliest biothreat pathogens.

    QuantuMDx Eyeing 2015 Launch of Handheld POC MDx Device

    Article: Breaking News—in PCR

    NEW YORK (GenomeWeb News) – After years in development, a handheld point-of-care molecular diagnostic device from QuantuMDx is poised to hit the market next year with malaria and tuberculosis as its initial target markets, a company executive said last week on the sidelines of the 32nd Annual JP

    Proteomics Notches Significant Successes in 2013, but Clinical Potential Still Largely Unfulfilled

    Article: In-Depth—in Proteomics & Protein Research

    2013 proved an eventful year for proteomics as the field saw milestones ranging from the release of long-awaited clinical tests to key regulatory clearances to noteworthy new instrument launches.

    Weak Guidance Leads to Hologic Downgrade

    Article: Breaking News—in PCR

    NEW YORK (GenomeWeb News) – Following Hologic's announcement that its Fiscal Year 2014 revenues will be down year over year, investment firm William Blair today downgraded the firm's stock to Market Perform from a previous rating of Outperform.

    Originally published April 12.

    This article has been updated from a previous version to correct the names of an individual and research institution.


A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.